Navigation Links
Study Published in Nature Biotechnology Demonstrates Ability of Moderna's Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
Date:9/8/2013

Chien. "Over the past 20 years, many labs have attempted to repair damaged heart muscle in animal models by delivering VEGF-A and other factors to the heart using recombinant proteins, DNA plasmids, and engineered viruses—with little if any clinical success. The results we have seen using messenger RNA therapeutics™ mark the start of a new and exciting phase of drug development with potentially profound implications for patients."

In the study, the mice injected with VEGF-A-coded messenger RNA produced a "pulse-like" expression of a significant quantity of VEGF-A near the injection site. The production of VEGF-A in turn mobilized heart progenitor cells to produce functional, intact blood vessels in the heart and led to marked improvements in heart function and improved long-term survival of the mice for at least one year post-MI. Researchers attribute these effects to a reduction in the size of infarct region and an increase in capillary density in the affected region. In this way, the high-level, transient production of VEGF-A led to a sustained therapeutic improvement by altering the behavior of heart progenitor cells. 

Introduction of modRNA was not associated with an innate immune response, further supporting the safety and effectiveness of this novel approach.

"We are extremely proud that our messenger RNA therapeutics™ platform enabled Ken to realize his vision and clinical intuition of the last 20 years," said Stephane Bancel, president and founding CEO of Moderna. "Beyond the considerable implications for the treatment of heart injury, this publication provides an important validation of the potential of messenger RNA therapeutics™ across a wide range of diseases. The ability to stimulate protein production within cells will enable the treatment of many diseases that cannot be addressed today. What is also exciting is the fact that the Moderna team has considerably improved our
'/>"/>

SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. iLab Solutions Announces the Results of the 2013 Core Facility Benchmarking Study
2. ResearchMoz.us: Private Healthcare Market - Investigation, Study, Size, Share in Central Europe and Poland and Poland 2013
3. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
4. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
5. Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients
6. MiMedx Plantar Fasciitis Study Published In The Foot & Ankle International Journal
7. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
8. BioStorage Technologies Launches INTEGRITY Study to Measure Effect of Time, Temperature and Preparation Methods on DNA and RNA Samples
9. Study Scavenger and CenterWatch Partner to Improve Patient Recruitment, Enrollment and Mobile Access to Clinical Trials with New Study Scavenger Smartphone App
10. VG Energy Chief Scientist Awarded $200,000 AgriLife Grant to Study Lipid Secretion
11. ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 According to ... (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, ... Preclinical, Clinical Trial), by End Users - Global Forecast ... expected to reach USD 2,107.99 million by 2020 from ... 15.29%. Browse more than ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... ... partnership with sanofi-aventis , ... Cambridge, MA (PRWEB) April 7, 2010 -- Merrimack Pharmaceuticals, Inc., a privately held ... inflammation, today announced that William Sullivan has been promoted to Vice President of Finance. ...
... , ... Business and Unveils a New Corporate Look , ... (PRWEB) April 5, 2010 -- HealthTalker , the leader in ... interactive Web site and a new Massachusetts headquarters. HealthTalker also reported strong revenue and ...
... pull on a single atom oflet,s saygold to detach it ... a measure of the astonishing progress in nanotechnology that questions ... now being asked by engineers. To help with the answers, ... Technology (NIST) has built an ultra-stable instrument for tugging on ...
Cached Biology Technology:Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance 2HealthTalker Programs Leveraging the Power of Word of Mouth Find Huge Success for Pharmaceutical Industry 2HealthTalker Programs Leveraging the Power of Word of Mouth Find Huge Success for Pharmaceutical Industry 3NIST researchers holding steady in an atomic-scale tug-of-war 2
(Date:7/31/2015)... The 10 th International Conference on Genomics (ICG-10, ... in Shenzhen , China ... anniversary this year. Since its inauguration in 2006, ICG ... in the ,omics, fields, and is one of the most ... focuses on recent breakthroughs and advances in ,omics, research that ...
(Date:7/23/2015)... July 23, 2015 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its second quarter ended June 30, ... 2015 was $4.5 million, a decrease of 33% compared to ... in the second quarter of 2015 was $0.3 million, or ... $0.04 per diluted share, in the same period a year ...
(Date:7/21/2015)... YORK , July 21, 2015 ... systems, as seen in the recent U.S. Office ... a solution to the infosec conundrum, but developers ... is stored. To address this dilemma, Biometrics-as-a-Service provider ... its Biometric Tokenization SDK for third party integration. ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... Health announced today that the University of Cincinnati will ... Science Award (CTSA) consortium. Led by the National Center ... national network of medical research institutions is working together ... treatments for patients, to engage communities in clinical research ...
... Authentication Technology Adds Robust Biometric Identification to ... ComplianceSUNNYVALE, Calif., April 6 Fujitsu Computer ... of innovative computer products including hard disk ... announced the integration of its ...
... (IODP), the world,s largest ocean research program, has ... by welcoming Australia, India, and New Zealand as ... membership is agreed upon in a memorandum signed ... Japan,s Ministry of Education, Culture, Sports, Science and ...
Cached Biology News:NIH Clinical and Translational Science Consortium grows to 39 members 2Fujitsu PalmSecure LOGONDIRECTOR Integrates with Passlogix v-GO Access Accelerator Suite 2Fujitsu PalmSecure LOGONDIRECTOR Integrates with Passlogix v-GO Access Accelerator Suite 3Fujitsu PalmSecure LOGONDIRECTOR Integrates with Passlogix v-GO Access Accelerator Suite 4Australia, India, New Zealand join integrated ocean drilling program 2
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: